Monograph Details
|
|
Urogenital System
> Benign prostatic hyperplasia/urinary retention
|
|
HYTRIN |
| Manufacturer |
|
Abbott Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
α1-blocker (quinazoline). |
| Generic Name |
|
Terazosin (as HCl) 1mg, 2mg, 5mg, 10mg; caps. |
| Indications |
|
BPH. |
| Children |
|
Not applicable. |
| Adults |
|
See literature. Initially 1mg at bedtime. Titrate to 10mg once daily; usual max 20mg/day. Reevaluate if no response after 6 weeks. |
| Precautions |
|
Rule out prostate cancer. Syncope. |
| Interactions |
|
Caution with verapamil, other antihypertensives. |
| Adverse Reactions |
|
Syncope (esp. 1st dose), dizziness, somnolence, asthenia, nausea, nasal congestion, palpitations, impotence, orthostatic hypotension, blurred vision, peripheral edema; priapism (rare). |
| How Supplied |
|
Caps—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
